COATS LONNEL 4

What Happened Lonnel Coats, a director of Relay Therapeutics, was granted an option covering 32,947 shares of the company's common stock on June 9, 2026. The Form 4 reports the grant as a derivative acquisition at $0.00 (the filing shows an award/option grant, not an open-market purchase or sale). This is a compensation award rather than an immediate cash transaction or sale.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 10, 2026 (timely filing).
• Grant: option covering 32,947 shares; reported price $0.00 (derivative award).
• Shares owned after transaction: not reported in the provided filing details.
• Footnote: the option vests in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
• No 10b5-1 plan, tax-withholding sale, or immediate sale noted in the supplied data.

Context This transaction is an equity-compensation grant to a director. Option grants give the holder the right to buy shares in the future (subject to vesting and exercise terms) and do not represent an immediate purchase or sale of stock. Director grants are common and are primarily a compensation matter rather than a direct bullish or bearish trading signal.